pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

MassBio CEO warns 2025 may be biotech's toughest year amid China and NIH challenges

Aug 26, 2026·read at Endpoints ↗Negative

Massachusetts is widely regarded as the epicenter of biotech because of its world‑class research institutions and vibrant startup ecosystem.

MassBio CEO Kendalle Burlin O’Connell said 2025 will probably be the most challenging year she can remember, pointing to hurdles in China and with the NIH.

The remarks underscore growing uncertainty for the region’s biotech sector and may prompt caution among investors and companies.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “MassBio report details challenges spanning China, NIH”

read at Endpoints ↗
89 words · retrieved 28m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoCellares rebukes Bristol Myers' criticism of its cell therapy technologyEndpoints
  • 1h agoBiohaven strikes $795M deal for commercial partner in epilepsyEndpoints
  • 3h agoHaisco grants license to Sentivera; ViiV's HIV treatment OK'd for newbornsEndpoints
  • 3h agoFDA approves Revolution Medicines' pancreatic cancer drugEndpoints
  • 4h agoAn uncertain future for Aurora, the first startup dedicated to custom CRISPR therapiesEndpoints